The marketing authorisation for Meloxivet has been withdrawn at the request of the marketing authorisation holder.
Meloxivet : EPAR - Summary for the public (PDF/218.3 KB)
First published: 28/11/2007
Last updated: 28/05/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
Eli Lilly and Company Limited
|Date of issue of marketing authorisation valid throughout the European Union||
28/05/2014 Meloxivet - EMEA/V/C/000124 - IG/0437
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.